Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASCE Plus SRLV (Skin Regenerative Lyophilized Vial) is a professional-grade aesthetic biologic developed by ExoCoBio, a South Korean biotechnology company specializing in exosome-based therapeutics. The product utilizes patented ExoSCRT technology to deliver high-purity exosomes derived from human adipose-derived stem cells (ASCs). ASCE Plus SRLV is designed to address skin aging, inflammatory conditions, and barrier dysfunction. It typically consists of two components: a lyophilized powder (Vial 1) containing approximately 5 billion exosomes along with growth factors and cytokines, and an activating solution (Vial 2) containing hyaluronic acid, amino acids, vitamins, and minerals. When administered via professional methods such as microneedling or mesotherapy, it promotes fibroblast proliferation, increases collagen and elastin production, and reduces pro-inflammatory markers, making it effective for skin rejuvenation and the management of conditions like atopic dermatitis and acne.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ASCE Plus SRLV.